Belviq Recall: Side Effects, Cancer Risk, and Where Claims Stand
If you took Belviq for a year or two, lost some weight, and only later learned the FDA had asked for it to be pulled, you probably have one question: did it do something to me? The drug was withdrawn in February 2020 after a large safety trial showed more cancers in people taking it than in people on a placebo. This post covers what Belviq was, its known side effects, why it came off the market, and what the litigation looks like now. For anyone with a cancer diagnosis after using it, a product liability lawyer at Boesen Law can review whether a claim is still open.
How Belviq Worked and What It Promised
Belviq was the brand name for lorcaserin, approved by the FDA in 2012 as a prescription aid for chronic weight management. It was developed by Arena Pharmaceuticals, and by the time of the withdrawal both the original tablet and the once-daily Belviq XR, approved in 2016, were held by Eisai. It was meant for adults with a body mass index of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes.
The drug acted on serotonin 2C receptors in the brain, the ones tied to appetite, to help people feel full sooner. The results were modest. In the two year-long trials described on the Belviq prescribing label, about 47 percent of patients without diabetes lost at least 5 percent of their body weight, compared with about 23 percent on placebo, and the average weight loss beyond placebo was 3.3 kilograms, roughly 7 pounds. The label told doctors to stop the drug if a patient had not lost 5 percent by week 12.
Those numbers matter for a claim, because a drug with limited benefit carries less room for risk. Boesen Law weighs that balance when we look at what a manufacturer knew and what it told patients.
For answers to your questions, call:
(303) 999-9999
Belviq and Belviq XR Side Effects
The label separated everyday side effects from the serious warnings. Here is what patients and doctors were told:
- Common effects without diabetes. Headache, dizziness, fatigue, nausea, dry mouth, and constipation were the most frequent complaints.
- Common effects with type 2 diabetes. Low blood sugar, headache, back pain, cough, and fatigue led the list, and weight loss itself could push blood sugar too low for people on diabetes medication.
- Serotonin syndrome. Because lorcaserin acts on serotonin, combining it with antidepressants such as SSRIs, bupropion, tramadol, and similar drugs carried a risk of this potentially life-threatening reaction.
- Heart valve problems. The label warned about regurgitant valve disease and told doctors to evaluate patients who developed shortness of breath, swelling, or a new heart murmur.
- Attention and memory problems. Impairments in attention and memory were reported in 1.9 percent of patients on Belviq versus 0.5 percent on placebo, and the label cautioned against driving until patients knew how it affected them.
- Mood and psychiatric effects. Euphoria, hallucinations, and dissociation appeared at high doses, and doctors were told to watch for depression or suicidal thoughts.
- Priapism. Patients were told to seek emergency care for an erection lasting more than four hours.
The heart valve warning will sound familiar to anyone who remembers Fen-Phen, the diet drug combination pulled in 1997. Boesen Law’s founder, Jon C. Boesen, represented more than 4,000 claimants nationwide in the Fen-Phen litigation, so the firm has seen how weight-loss drug injuries unfold over years, not months.
Why the FDA Pulled Belviq: The Recall Timeline
The cancer signal came out of a trial the FDA required as a condition of approval. The key dates:
- 2012. The FDA approves Belviq and requires the manufacturer to run a large trial on heart safety.
- January 2014 to June 2018. About 12,000 patients take part in the CAMELLIA-TIMI 61 trial.
- January 14, 2020. The FDA announces that the trial shows a possible increased risk of cancer and says it is still evaluating the data.
- February 13, 2020. The FDA requests that Belviq and Belviq XR be withdrawn and the manufacturer voluntarily pulls it. In the trial, 462 patients on lorcaserin (7.7 percent) were diagnosed with cancer, compared with 423 on placebo (7.1 percent). Pancreatic, colorectal, and lung cancers appeared more often in the lorcaserin group.
- March 4, 2021. The FDA publishes a Federal Register determination that Belviq was withdrawn for reasons of safety or effectiveness, so the agency will not approve generic lorcaserin.
At the withdrawal, the FDA told patients to stop taking Belviq and told doctors to stop prescribing it. The agency also said it was not recommending special cancer screening for people who had taken it. If you have a diagnosis, the dates of your prescriptions against this timeline are the first thing Boesen Law will ask about.
Where Belviq Lawsuits Stand Now
A cancer signal in a trial is not the same thing as proof in court, and the Belviq litigation never grew into the large, coordinated case many people expected.
No Federal MDL
In August 2021, the Judicial Panel on Multidistrict Litigation declined to centralize the Belviq cases. At the time there were 13 federal lawsuits in 10 districts, and the panel found that each plaintiff’s cancer, exposure length, and causation questions were too individual to manage together. The cases went forward one at a time.
Few Public Outcomes
There has been no public global settlement and no widely reported jury verdict. Some individual cases have reportedly resolved on confidential terms, and many firms that advertised for Belviq cases have stopped taking new ones. Anyone telling you there is a Belviq settlement fund waiting to be claimed is not describing the real picture.
Deadlines Are the Biggest Hurdle
Under C.R.S. § 13-80-106, a Colorado lawsuit against a drug manufacturer generally has to be filed within two years, and C.R.S. § 13-80-108 starts that clock when you knew or should have known about both the injury and its likely cause. With the withdrawal now more than six years old, the time limits on personal injury cases have likely closed older claims. A recent diagnosis, a death in the family, or a patient who was a minor or under a legal disability can change the math, so Boesen Law checks the dates before telling anyone no.
Today’s Weight-Loss Drug Claims Look Different
Belviq was a pill that worked on brain chemistry. The weight-loss drugs driving new lawsuits today are injectable GLP-1 medications such as Ozempic and Wegovy, and the injuries alleged are different: severe stomach paralysis, bowel obstruction, and other gastrointestinal harm, along with a type of sudden vision loss.
Federal GI injury cases over these drugs are consolidated in MDL No. 3094 in the U.S. District Court for the Eastern District of Pennsylvania. If you took a GLP-1 drug and were hospitalized, Boesen Law is reviewing GLP-1 lawsuit claims for Colorado patients now, while the deadlines are still running.
Barry I. Dunn on Drug Claims After a Recall
Barry I. Dunn, whose 31 years of trial work include product liability cases over defective pharmaceutical drugs, explains:
“A recall letter is where most people’s questions start, not where a case starts. When someone calls about Belviq, I want the prescription history first: when they started, how long they stayed on it, and when the cancer was found. Then I look hard at their other risk factors, because the defense will. I have filed hundreds of lawsuits when insurers and companies would not make a fair offer, and I do not file one until the medical proof is lined up. If a Belviq claim is out of time, I would rather tell a client that on day one and look at whether something else in their care went wrong.”
That review costs you nothing, and it often turns up questions about the medical care that followed a diagnosis as well as the drug itself.
What Cases Like Yours Have Recovered
Injuries caused in a medical setting can be permanent, and the firm pursues them with the same care as any drug claim. In one case, a nerve block placed incorrectly during surgery to remove a leg tumor damaged the client’s deep peroneal nerve and left the client largely wheelchair-bound; Boesen Law recovered $500,000. You can review more of our case results from across Colorado.
Tell us what happened, and we will tell you what we see.
Talk to Boesen Law About a Weight-Loss Drug Injury
A drug you trusted to help your health should not leave you wondering what it did to you. We fight for the maximum compensation you deserve when a drug maker or a medical provider falls short, and we will give you an honest read on whether your Belviq, GLP-1, or other medication history supports a claim.
Consultations are free and in person, with calls answered 24 hours a day, 7 days a week. Our injury cases are handled on contingency, which means no attorney fee unless we recover compensation for you. To get started, contact Boesen Law by phone or online.
FAQs About the Belviq Recall and Side Effects
Is Belviq still available?
No. Belviq and Belviq XR have been off the U.S. market since February 2020, and the FDA’s 2021 determination means no generic version of lorcaserin will be approved as things stand. If you still have old tablets, the FDA’s advice was to stop taking them, mix them with something unappealing like used coffee grounds or cat litter, seal them in a bag, and throw them away.
How much weight did people lose on Belviq?
In the year-long trials on the label, patients without diabetes lost an average of about 5.8 percent of their body weight on Belviq versus about 2.5 percent on placebo. Roughly 22 percent of Belviq patients lost 10 percent or more, compared with about 9 percent on placebo.
What are the common side effects of Belviq?
Headache, dizziness, fatigue, nausea, dry mouth, and constipation were most common in people without diabetes. In people with type 2 diabetes, low blood sugar, headache, back pain, cough, and fatigue topped the list. Serious risks included serotonin syndrome, heart valve problems, memory and attention trouble, and mood changes.
What is the safest weight-loss drug you can take?
There is no single safest option, because the right medication depends on your health history, other prescriptions, and goals, and that is a conversation for your doctor. Every weight-loss drug carries tradeoffs. The newer GLP-1 drugs, for example, have been linked in lawsuits to gastroparesis, a condition in which the stomach empties far too slowly.
Should I get screened for cancer because I took Belviq?
When it requested the withdrawal, the FDA said it was not recommending special screening for people who had taken lorcaserin. Talk to your doctor about the standard screenings for your age and history, and tell them you took Belviq so it is in your chart.
Call (303) 999-9999 or complete a Free Case Evaluation form
Content Reviewed By
